Media Newsroom of
DelveInsight
DelveInsight is a Business Consultant and Knowledge Partner and have extensive experience across the value chain of pharmaceutical industry. Our company can provide valuable insight across all Pharmaceutical industries which include Drug Manufacturing to API Manufacturers to Drug Research Companies. We can help you in building clients for your business and can help you in expanding your business while providing you the marketing strategies and therefore enabling you to grow revenue. Our team of experts can analyze your current business practices and streamline your processes to increase your return on investment.
Natural Killer Cells Therapies- Competitive Landscape, Technology and Pipeline Analysis, 2017
The Report covers 20+ companies, which are active in this field with 40+ products and many different technologies. This report covers NK cell-based therapies along with drugs that augment (enhance or activate) the NK cells. The Report provides in-depth analysis…
Chimeric Antigen Receptor (CAR)T cell Immunotherapy- Competitive Landscape, Technology and Pipeline
DelveInsight's Report, "Chimeric Antigen Receptor (CAR) T-cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2017" emphasizes on the currently active CAR-T cell products in research and development.The Report covers the 68+ companies, which are active in this field including 29+…
Microbiome-Competitive Landscape, Technology and Pipeline Analysis, 2017
DelveInsight's, "Microbiome-Competitive Landscape, Technology and Pipeline Analysis, 2017", the report provides comprehensive insights about microbiome based therapeutic pipeline products. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under this category.This…
Immune Checkpoints Activators: Competitive Landscape, Technology and Pipeline Analysis 2017
This report provides information on the therapeutic development based on Immune Checkpoints Activation mechanism dealing with 3 Phase II, 16 Phase I drugs and 19Preclinical and Discovery drugs. The report also covers the information for 20+ active companies involved in…